Technology offer
The Germans Trias i Pujol Research Institute (IGTP) promotes the transfer of scientific knowledge to the healthcare system and the productive sector through the development of innovative solutions in diagnostics, therapy and medical technology. This technology portfolio brings together innovative projects from the Institute's research groups, classified by type and therapeutic area.
The Institute seeks to collaborate with companies, investors and institutions interested in licensing, co-developing or validating technologies with clinical and market potential. Through these partnerships, it aims to accelerate the translation of innovation to patients and contribute to a more effective, sustainable and evidence-based healthcare system.
| PROJECT | AREA | TYPE | OBJECTIVE | STAGE | |||||
| ABEONA | Oncology | Medical Device | Digital application for the prevention of chemotherapy-induced toxicity in colorectal cancer patients. The solution uses a SaaS and DaaS model to monitor patients in real time, detect early signs of toxicity and adapt treatment in a personalised way, improving safety and quality of life. | Proof of concept | |||||
| ANALIFT | Community Health | Medical Device | Connected medical device linked to a gamified mobile app that enables home-based biofeedback training to improve sphincter control and pelvic floor health. It facilitates rehabilitation outside the hospital and encourages treatment adherence. | Technological feasibility | |||||
| Apotransferrin for stroke treatment | Neurology | Therapy |
|
Preclinical validation | |||||
| BIOMARKIDS | Oncology | IVD | Clinical support tool based on molecular analysis and data algorithms to improve risk stratification in paediatric patients with hepatoblastoma. It optimises diagnostic classification and tailors treatment according to each patient's prognostic profile. | Technological feasibility | |||||
| BLEBMAKER | Ophthalmology | Medical Device |
|
Technological feasibility | |||||
| CHILD | Oncology |
|
Novel targeted therapeutic strategy for the treatment of paediatric hepatoblastoma. Based on an innovative translational medicine approach, the project aims to enhance treatment efficacy and reduce adverse effects in children. | Proof of concept | |||||
| CS4P | Cardiology | IVD | In vitro diagnostic test based on a panel of four proteins that enables short-term mortality risk prediction in patients with cardiogenic shock, helping physicians optimise treatment and improve clinical prognosis. | Technological development | |||||
| DELIRIUM-IA | Community Health | Medical Device | Artificial intelligence tool designed to detect and prevent hospital delirium. It combines a predictive algorithm with an interactive device that stimulates and assesses the patient's cognitive state. | Proof of concept | |||||
| Disinfectant against Legionella | Infectious Diseases | Biocide | New generation of biocidal compounds that act effectively against Legionella in all its forms - planktonic, biofilm and intracellular - preventing recolonisation and ensuring safer, longer-lasting disinfection. | Proof of concept | |||||
| DetectAR | Oncology | Medical Device | DetectAR is a localisation system for non-palpable lesions in oncological surgery that uses augmented reality to display in real time the exact area to be resected, improving precision, reducing reoperations and costs, and optimising surgical workflow. | Technological feasibility | |||||
| HEMOSHAKE | Nephrology | Medical Device | Technology that improves haemodialysis efficiency by applying controlled external energy to break the bond between toxins and blood proteins, facilitating their removal during treatment and improving survival and quality of life in patients with chronic kidney disease. | Proof of concept | |||||
| INCARE 2.0 | Community Health | Medical Device | Digital solution powered by artificial intelligence to detect and monitor complex wounds via mobile devices, improving early diagnosis and reducing complications and costs. | Proof of concept | |||||
| LEWY-DX | Neurology | IVD | In vitro diagnostic test based on the analysis of platelet miRNA that accurately differentiates dementia with Lewy bodies from Alzheimer's disease, improving diagnosis, clinical management and personalised treatment. | Technological development | |||||
| NANORADIOMED | Oncology | Medical Device | Formulation based on nanoparticles for the controlled release of active ingredients that prevent radiodermatitis in women undergoing radiotherapy for breast cancer, improving skin tolerance and quality of life during treatment. | Technological feasibility | |||||
| NF2 RESTORE | Oncology | Therapy | RNA-based gene therapy for the treatment of schwannomatosis related to the NF2 gene. It uses modified RNA molecules to restore NF2 gene function or block the effects of pathogenic mutations. | Proof of concept | |||||
| NEUROACTIVE | Neurology | Therapy | Innovative therapeutic platform focused on modulating neuronal activity to restore brain function in neurodegenerative diseases. It combines biotechnology and precision approaches to improve synaptic plasticity and functional recovery. | Technological feasibility | |||||
| RADIOLUNG | Pneumology | Medical Device |
|
Technological development | |||||
| RACEPLUS | Neurology | Medical Device | Artificial intelligence-based application for the diagnosis and management of stroke in prehospital settings. It integrates clinical data and the RACE scale score to rapidly and accurately predict stroke type and identify large vessel occlusion (LVO) candidates for endovascular treatment. | Proof of concept | |||||
| RESISTA | Infectious Diseases | Therapy | New antimicrobial treatment for infections caused by multidrug-resistant Staphylococcus aureus (including MRSA), initially aimed at treating sepsis and skin infections, and later prosthetic joint infections. | Technological feasibility | |||||
| RUSH-PoC | Neurology | IVD | Rapid diagnostic test to distinguish between ischaemic and haemorrhagic stroke before hospital arrival, aiming to reduce treatment time and improve patient recovery. | Technological feasibility | |||||
| RUTIGLOVES | General Surgery | Medical Device | New formulation for manufacturing surgical gloves with enhanced puncture resistance to improve protection and reduce infection risk among healthcare professionals. | Proof of concept | |||||
| RUTIEBUS | Pneumology | Medical Device | Next-generation bronchoscopy system based on miniaturised probes that enables precise navigation through the airways. It facilitates safer diagnosis and treatment of pulmonary diseases. | Technological feasibility | |||||
| RUTIPASTE | General Surgery | Medical Device | Bioabsorbable sealant designed to prevent post-surgical tissue leaks. It provides immediate adhesion in wet tissue and structural support, reducing complications and improving patient recovery. | Technological development | |||||
| RUTISETON | Community Health | Medical Device | New seton device with simplified closure and a flexible tip that allows use without surgery or general anaesthesia, reducing treatment time and patient discomfort. | Proof of concept | |||||
| SNIPer | Oncology | Medical Device | Innovative medical device that enables image-guided surgical interventions and tumour cell elimination through light. Integrated into existing systems, it allows precise resection and localised cancer treatment in real time. | Proof of concept | |||||
| TB-OMICS | Infectious Diseases | IVD | Innovative diagnostic method based on the identification of metabolomic signatures in urine samples to detect tuberculosis rapidly, non-invasively and in resource-limited settings. | Technological development | |||||
| THYROMET | Oncology | IVD | In vitro test based on DNA methylation biomarkers that predicts metastasis risk in thyroid cancer patients. It supports treatment personalisation, prevents overtreatment and improves patient prognosis and quality of life. | Proof of concept | |||||
| VESICLE-X | Digestive Diseases | Therapy | Biomedical device based on extracellular vesicles designed to prevent postoperative recurrence in Crohn's disease patients. It offers a new biological therapeutic approach with local regenerative and anti-inflammatory capacity. | Proof of concept | |||||